Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NNC0174-0833 Clear all
Completed Phase 1 Interventional

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

NCT03787225
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

NCT02300844
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0174-0833, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 64 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

NCT03600480
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Semaglutide, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

NCT02958085
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0174-0833, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT05016882
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
70
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 2 Interventional Results available

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

NCT03856047
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Anaheim, California • Spring Valley, California • Crystal River, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 4, 2026, 2:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

NCT03617081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0113-2023, Placebo (NNC0113-2023)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 4, 2026, 2:19 AM EDT